as well as antibodies isolated from humans who had recovered from COVID-19. Scientists from Regeneron selected the two most potent, non-competing virus-neutralising antibodies and scaled up ...

Antibody treatments for COVID-19 are currently in the spotlight after it emerged that president Donald Trump received treatment with a rival cocktail from Regeneron. The Regeneron therapy is still ...

A study on bat genomes, involving Texas Tech University, discovered genetic adaptations that help bats resist viral ...

Acceptance follows resolution of third-party fill/finish manufacturing issuesFDA decision expected by July 10, 2025 TARRYTOWN, N.Y., Feb. 11, ...

Regeneron settles patent lawsuit over protein for testing COVID-19 treatments December 16, 2024 AnaptysBio will end the development of its experimental drug to treat eczema as the treatment failed ...

Regeneron (REGN) and Sanofi (SNY ... whose disease is not adequately controlled with H1 antihistamine treatment. The target action date for the FDA decision is April 18, 2025.

Regeneron Pharmaceuticals Inc. (REGN) announced encouraging outcomes from the Phase 3 QUASAR trial, which evaluated the efficacy of ...

Regeneron Pharmaceuticals today announced financial results for the fourth quarter and full year 2024 and provided a business ...

Regeneron Pharmaceuticals announced positive ... of EYLEA HD's effectiveness and support its potential to reduce treatment burdens for elderly patients. At three years of treatment with EYLEA ...

This includes more than $3 billion in COVID-19 vaccine sales and minimal sales from the RSV vaccine mResvia. This figure was mainly toward the lower end of the company’s previously issued ...

(RTTNews) - Regeneron Pharmaceuticals Inc. (REGN ... the known safety profile of EYLEA HD in its pivotal trials. Ocular treatment-emergent adverse events (TEAEs) occurring in greater than or ...